Citation: | WANG Shaojie, LI Xiaojie, XU Zhimeng, YAN Kang, CHEN Xi, JIANG Zhenzhou, ZHANG Luyong. Improvement of emodin on acute fatty liver in mice[J]. Journal of China Pharmaceutical University, 2017, 48(1): 89-95. DOI: 10.11665/j.issn.1000-5048.20170114 |
[1] |
Hardwick JP,Osei-Hyiaman D,Wiland H,et al.PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase(CYP4)isozymes:implications for prevention of lipotoxicity in fatty liver disease[J].PPAR Res,2009,2009:952734.
|
[2] |
Portincasa P, Grattagliano I, Palmieri VO, et al. Nonalcoholic steatohepatitis:recent advances from experimental models to clinical management[J].Clin Biochem,2005,38(3):203-217.
|
[3] |
Xue J,Ding W,Liu Y.Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice[J].Fitoterapia,2010,81(3):173-177.
|
[4] |
Song P,Kim JH,Ghim J,et al.Emodin regulates glucose utilization by activating AMP-activated protein kinase[J].J Biol Chem,2013,288(8):5732-5742.
|
[5] |
Heo SK, Yun HJ, Park WH, et al. Emodin inhibits TNF-alpha-induced human aortic smooth-muscle cell proliferation via caspase-and mitochondrial-dependent apoptosis[J].J Cell Biochem,2008,105(1):70-80.
|
[6] |
Wang CH, Gao ZQ, Ye B, et al. Effect of emodin on pancreatic fibrosis in rats[J].World J Gastroenterol,2007,13(3):378-382.
|
[7] |
Liu WH,Qi Y,Jia D.Research progress on experimental models of non-alcoholic fatty liver disease[J].Shanghai J Tradit Chin Med(上海中医药杂志),2015,49(3):95-97.
|
[8] |
Yoshizawa F,Mochizuki S,Doi M,et al.Ethionine-induced ATP depletion represses mTOR signaling in the absence of increases in AMP-activated protein kinase activity in the rat liver[J].Biosci Biotechnol Biochem,2009,73(9):1984-1988.
|
[9] |
Yu HY,Wang BL,Zhao J,et al.Protective effect of bicyclol on tetracycline-induced fatty liver in mice[J].Toxicology,2009,261(3):112-118.
|
[10] |
Choi YJ, Lee CH, Lee KY, et al. Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice[J].Toxicol Sci,2015,145(2):273-282.
|
[11] |
BénichouC.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatol,1990,11(2):272-276.
|
[12] |
Kohjima M,Enjoji M,Higuchi N,et al.Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease[J].Int J Mol Med,2007,20(3):351-358.
|
[13] |
Raghow R,Yellaturu C,Deng X,et al.SREBPs:the crossroads of physiological and pathological lipid homeostasis[J].Trends Endocrinol Metab,2008,19(2):65-73.
|
[14] |
Browning JD,Horton JD.Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest,2004,114(2):147-152.
|
[15] |
Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice[J].Cell Metab,2011,13(4):376-388.
|
[1] | WANG Songkai, ZOU Yuchen, SUN Shipeng, YAN Zhiye, TANG Weiwei, LI Ping, LI Bin. Recent advances in mass spectrometry imaging and its application in drug research[J]. Journal of China Pharmaceutical University, 2023, 54(6): 653-661. DOI: 10.11665/j.issn.1000-5048.2023091901 |
[2] | FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406 |
[3] | ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403 |
[4] | WEI Yuanyuan, YANG Fan, TANG Jie, YU Lifang. Advances in the research of anti-tuberculosis drugs[J]. Journal of China Pharmaceutical University, 2020, 51(2): 231-239. DOI: 10.11665/j.issn.1000-5048.20200215 |
[5] | HAN Xiu, QI Xiaole, WU Zhenghong. Advances in self-assemblied DNA nanocages as drug delivery systems[J]. Journal of China Pharmaceutical University, 2017, 48(6): 663-669. DOI: 10.11665/j.issn.1000-5048.20170605 |
[6] | CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203 |
[7] | JIANG Lu, CHEN Dandan, SUN Minjie, PING Qineng, ZHANG Can. Advances of wax matrix tablets[J]. Journal of China Pharmaceutical University, 2016, 47(4): 497-502. DOI: 10.11665/j.issn.1000-5048.20160418 |
[8] | YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417 |
[9] | LIU Yanhong, ZHOU Jianping, HUO Meirong. Advances in the tumor microenvironment-responsive smart drug delivery nanosystem[J]. Journal of China Pharmaceutical University, 2016, 47(2): 125-133. DOI: 10.11665/j.issn.1000-5048.20160201 |
[10] | WANG Ruoning, LIU Congyan, ZHOU Jianping, CHEN Jian, WANG Wei. Advances in the research of lipoprotein-based nano scale drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(1): 10-16. DOI: 10.11665/j.issn.1000-5048.20140102 |